These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34347396)

  • 1. Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of
    Zhou X; Xiao Q; Fu D; Zhang H; Tang Y; He J; Hu Y; Kong X; Teng F; Liu X; Yuan Y; Ding K
    Cancer Biol Med; 2021 Aug; 19(2):213-28. PubMed ID: 34347396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy and side effects of rigosertib combined with chemotherapy in
    Zhang HC; Zhou XY; Fu DL; Ding YW; Xiao Q; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):138-145. PubMed ID: 36781234
    [No Abstract]   [Full Text] [Related]  

  • 3. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway.
    Rahmani F; Hashemzehi M; Avan A; Barneh F; Asgharzadeh F; Moradi Marjaneh R; Soleimani A; Parizadeh M; Ferns GA; Ghayour Mobarhan M; Ryzhikov M; Afshari AR; Ahmadian MR; Giovannetti E; Jafari M; Khazaei M; Hassanian SM
    Cell Signal; 2021 Sep; 85():110069. PubMed ID: 34214591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
    Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
    Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibitors and DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, prevent the migration and invasion of KRAS-mutant cancer cells.
    Matsuda A; Masuzawa R; Takahashi K; Takano K; Endo T
    Cytoskeleton (Hoboken); 2024 Jun; ():. PubMed ID: 38872577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor.
    Liu Y; Cheng Y; Huang G; Xia X; Wang X; Tian H
    Front Pharmacol; 2023; 14():1271268. PubMed ID: 37808191
    [No Abstract]   [Full Text] [Related]  

  • 10. Rigosertib promotes anti-tumor immunity via autophagic degradation of PD-L1 in colorectal cancer cells.
    Zhou X; Fu D; Yang H; Le C; Lu Y; Wei J; Tang Y; Zhang J; Yuan Y; Ding K; Xiao Q
    Cancer Lett; 2023 Nov; 577():216422. PubMed ID: 37805162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.
    Dietrich P; Freese K; Mahli A; Thasler WE; Hellerbrand C; Bosserhoff AK
    Oncotarget; 2018 Jan; 9(3):3605-3618. PubMed ID: 29423069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 14. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
    Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
    Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
    Yan C; Saleh N; Yang J; Nebhan CA; Vilgelm AE; Reddy EP; Roland JT; Johnson DB; Chen SC; Shattuck-Brandt RL; Ayers GD; Richmond A
    Mol Cancer; 2021 Jun; 20(1):85. PubMed ID: 34092233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
    Tabusa H; Brooks T; Massey AJ
    Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CircRAPGEF5 acts as a modulator of RAS/RAF/MEK/ERK signaling during colorectal carcinogenesis.
    Yin Z; Li H; Zhao H; Bentum-Ennin L; Xia Y; Wang Z; Hu W; Gu H; Zhang S; Li G
    Heliyon; 2024 Aug; 10(16):e36133. PubMed ID: 39229520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
    Tamura S; Tazawa H; Hori N; Li Y; Yamada M; Kikuchi S; Kuroda S; Urata Y; Kagawa S; Fujiwara T
    PLoS One; 2023; 18(11):e0294491. PubMed ID: 37972012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells.
    Yao W; Lin Z; Shi P; Chen B; Wang G; Huang J; Sui Y; Liu Q; Li S; Lin X; Liu Q; Yao H
    Biochem Pharmacol; 2020 Jan; 171():113680. PubMed ID: 31669234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.